Scientific thomsonreuters.com

Biomarkers are becoming an essential part of clinical development. In a new white paper, Thomson Reuters explores the role of biomarkers as evaluative tools in improving clinical research, and their potential to improve decision making, accelerate drug development and reduce development costs.

Biomarkers — a measure of a normal biological process in the body, a pathological process, or the response of the body to a therapy — may offer information about the mechanism of action of a drug, its efficacy, its safety and its metabolic profile. There is wide consensus that biomarkers are and will be useful as evaluative tools in improving clinical research.

Biomarkers feature heavily in the FDA’s Critical Path Opportunities List for their potential to speed the development and approval of medical products. The FDA estimates that just a 10 per cent improvement in the ability to predict drug failures before clinical trials could save USD100 million in development costs per drug. Biomarkers also offer the potential to inform treatment decisions and to bring personalized medicine into clinical practice.

Read more about the potential of biomarkers in our free white paper

• PRIVACY POLICY
• TERMS OF USE
• COPYRIGHT
• CONTACT US